Nitric Oxide Regulates Adhesiveness, Invasiveness, and Migration of Anoikis-resistant Endothelial Cells

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2022 Feb 9

PMID 35137850

Authors

A P S Mesquita

M Matsuoka

S A Lopes

P C A Pernambuco Filho

A S Cruz

H B Nader

C C Lopes

Affiliations

Soon will be listed here.

Abstract

Anoikis is a type of apoptosis that occurs in response to the loss of adhesion to the extracellular matrix (ECM). Anoikis resistance is a critical mechanism in cancer and contributes to tumor metastasis. Nitric oxide (NO) is frequently upregulated in the tumor area and is considered an important player in cancer metastasis. The aim of this study was to evaluate the effect of NO on adhesiveness, invasiveness, and migration of anoikis-resistant endothelial cells. Here, we report that anoikis-resistant endothelial cells overexpress endothelial nitric oxide synthase. The inhibition of NO release in anoikis-resistant endothelial cells was able to decrease adhesiveness to fibronectin, laminin, and collagen IV. This was accompanied by an increase in cell invasiveness and migration. Furthermore, anoikis-resistant cell lines displayed a decrease in fibronectin and collagen IV protein expression after L-NAME treatment. These alterations in adhesiveness and invasiveness were the consequence of MMP-2 up-regulation observed after NO release inhibition. The decrease in NO levels was able to down-regulate the activating transcription factor 3 (ATF3) protein expression. ATF3 represses MMP-2 gene expression by antagonizing p53-dependent trans-activation of the MMP-2 promoter. We speculate that the increased release of NO by anoikis-resistant endothelial cells acted as a response to restrict the MMP-2 action, interfering in MMP-2 gene expression via ATF3 regulation. The up-regulation of nitric oxide by anoikis-resistant endothelial cells is an important response to restrict tumorigenic behavior. Without this mechanism, invasiveness and migration potential would be even higher, as shown after L-NAME treatment.

Citing Articles

Identification and clinical validation of the role of anoikis-related genes in diabetic foot.

Su N, Wang J, Zhang H, Jin H, Miao B, Zhao J Int Wound J. 2024; 21(3):e14771.

PMID: 38468369 PMC: 10928261. DOI: 10.1111/iwj.14771.

Zhao X, Wang Z, Tang Z, Hu J, Zhou Y, Ge J Front Oncol. 2023; 13:1169425.

PMID: 37664042 PMC: 10469923. DOI: 10.3389/fonc.2023.1169425.

ATF3 in atherosclerosis: a controversial transcription factor.

Wang B, Yang X, Sun X, Liu J, Fu Y, Liu B J Mol Med (Berl). 2022; 100(11):1557-1568.

PMID: 36207452 DOI: 10.1007/s00109-022-02263-7.

References

Carneiro B, Pernambuco Filho P, Mesquita A, da Silva D, Pinhal M, Nader H . Acquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells. PLoS One. 2014; 9(12):e116001. PMC: 4280138. DOI: 10.1371/journal.pone.0116001. View

Liang G, Wolfgang C, Chen B, Chen T, Hai T . ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem. 1996; 271(3):1695-701. DOI: 10.1074/jbc.271.3.1695. View

Vannini F, Kashfi K, Nath N . The dual role of iNOS in cancer. Redox Biol. 2015; 6:334-343. PMC: 4565017. DOI: 10.1016/j.redox.2015.08.009. View

Huang Z, Fu J, Zhang Y . Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. J Med Chem. 2017; 60(18):7617-7635. DOI: 10.1021/acs.jmedchem.6b01672. View

Smeda M, Kieronska A, Adamski M, Proniewski B, Sternak M, Mohaissen T . Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice. Breast Cancer Res. 2018; 20(1):86. PMC: 6091065. DOI: 10.1186/s13058-018-1013-z. View

Viappiani S, Nicolescu A, Holt A, Sawicki G, Crawford B, Leon H . Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol. 2008; 77(5):826-34. DOI: 10.1016/j.bcp.2008.11.004. View

McCabe T, Fulton D, Roman L, Sessa W . Enhanced electron flux and reduced calmodulin dissociation may explain "calcium-independent" eNOS activation by phosphorylation. J Biol Chem. 2000; 275(9):6123-8. DOI: 10.1074/jbc.275.9.6123. View

Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I . A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res. 2004; 10(3):1057-63. DOI: 10.1158/1078-0432.ccr-03-0047. View

Vitecek J, Lojek A, Valacchi G, Kubala L . Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges. Mediators Inflamm. 2012; 2012:318087. PMC: 3441039. DOI: 10.1155/2012/318087. View

10.

Simpson C, Anyiwe K, Schimmer A . Anoikis resistance and tumor metastasis. Cancer Lett. 2008; 272(2):177-85. DOI: 10.1016/j.canlet.2008.05.029. View

11.

Jablonska-Trypuc A, Matejczyk M, Rosochacki S . Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016; 31(sup1):177-183. DOI: 10.3109/14756366.2016.1161620. View

12.

Jacob-Ferreira A, Kondo M, Baral P, James M, Holt A, Fan X . Phosphorylation status of 72 kDa MMP-2 determines its structure and activity in response to peroxynitrite. PLoS One. 2013; 8(8):e71794. PMC: 3754950. DOI: 10.1371/journal.pone.0071794. View

13.

Lala P, Chakraborty C . Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2002; 2(3):149-56. DOI: 10.1016/S1470-2045(00)00256-4. View

14.

Kim Y, Koo K, Sung J, Yun U, Kim H . Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012; 2012:306879. PMC: 3296207. DOI: 10.1155/2012/306879. View

15.

Yan C, Wang H, Boyd D . ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter. J Biol Chem. 2002; 277(13):10804-12. DOI: 10.1074/jbc.M112069200. View

16.

Sugimoto M, Nakayama M, Goto T, Amano M, Komori K, Kaibuchi K . Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells. Biochem Biophys Res Commun. 2007; 361(2):462-7. DOI: 10.1016/j.bbrc.2007.07.030. View

17.

Gallo O, Masini E, Morbidelli L, Franchi A, Vergari W, Ziche M . Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998; 90(8):587-96. DOI: 10.1093/jnci/90.8.587. View

18.

Chen H, Wang D . Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol. 2004; 65(5):1130-40. DOI: 10.1124/mol.65.5.1130. View

19.

Guenzle J, Wolf L, Garrelfs N, Goeldner J, Osterberg N, Schindler C . ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NFB and STAT3 inhibition in glioblastoma. Cell Death Discov. 2017; 3:17006. PMC: 5327503. DOI: 10.1038/cddiscovery.2017.6. View

20.

Davis K, Martin E, Turko I, Murad F . Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol. 2001; 41:203-36. DOI: 10.1146/annurev.pharmtox.41.1.203. View